Cancer types · Blood cancers
Multiple Myeloma
Multiple myeloma is a cancer of plasma cells in the bone marrow. It can affect bones, kidneys and blood counts, and is often monitored using proteins measured in blood and urine.
Cytogenetic results help define risk and are a common focus of review questions.
Clinical and molecular questions that often arise
- What do FISH and cytogenetics show about risk?
- How is response being monitored (M-protein, light chains, MRD)?
- What do imaging and kidney function show?
- At relapse, what has changed?
Information that may be part of an individual assessment
- Serum and urine protein studies, including free light chains.
- Bone marrow examination with FISH and cytogenetics.
- Imaging of the skeleton.
- MRD testing in selected settings.
Which investigations are appropriate is decided by the treating team for each person.
Molecular profiling and biomarker interpretation
Depending on the setting, molecular and biomarker questions in multiple myeloma may involve:
- High-risk cytogenetics such as t(4;14), t(14;16), t(14;20), del(17p)/TP53 and 1q gain or amplification
- t(11;14), which has particular research and therapeutic relevance
- M-protein and free light-chain levels
Biomarkers, panels and available tests vary by subtype, disease setting, assay and guideline version. A detected alteration is not automatically actionable.
How KPCIRC pathways may apply
POAS
POAS may help organise cytogenetic and molecular findings, evidence strength and trial questions within the agreed haemato-oncology scope.
Molecular Tumour Board
Haemato-oncology or MTB discussion may help with high-risk features or relapse decisions.
Second opinion and progression review
A second opinion may help clarify risk and treatment planning. Progression review can organise markers and treatment lines.
Hereditary risk and screening
Multiple myeloma is not usually inherited, although familial clustering has been reported.
How to access the relevant pathway
Patients and families
- Talk to your treating oncologist about whether an additional review may help.
- Request a consultation and tell us which question you want answered.
- Share records only when asked, through the secure route.
Referring doctors
- Define the clinical question and the pathway: POAS, MTB, second opinion or progression review.
- Start a case enquiry without patient identifiers.
- Scope, fees and timing are confirmed before any review proceeds.
Questions and limitations
What does “high-risk” myeloma mean?
It refers to certain cytogenetic or clinical features associated with more aggressive disease. It is interpreted by the treating haematologist with other information.
Why are blood and urine proteins tested so often?
They help track how the disease responds to treatment over time.
Does this page apply to my situation?
This page is educational. It explains common questions but cannot account for individual circumstances. Your treating clinician is best placed to interpret your reports and plan your care.
Educational content reviewed against the KPCIRC service scope. It is not a diagnosis, a treatment recommendation or a statement that a specialist or service is available for this cancer type.